HHS CLINICAL TRIAL DATABANK WOULD EXEMPT INDUSTRY FROM DISCLOSURES INTERFERING WITH ENROLLMENT UNDER DODD AMENDMENT; COMPOUNDING ADDED TO FDA REFORM BILL
Companies would not be required to supply information relating to a clinical trial to an HHS database if the company can certify that "the disclosure of such information would substantially interfere with the timely enrollment of subjects in the investigation," according to language incorporated into the Senate Labor and Human Resources Committee FDA reform bill (S 830).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth